文献速递脊柱关节炎

脊柱关节炎中的神经病理性疼痛:解读其患病率、危险因素及对疾病活动度的影响

Neuropathic pain in spondyloarthritis: Decoding its prevalence, risk factors, and impact on disease activity.
PubMed 文献 · Semin Arthritis Rheum · 2024-09-27

这项在两家三级风湿病中心开展的横断面研究纳入177例脊柱关节炎(SpA)患者,包括中轴型SpA、银屑病关节炎和未分化外周型SpA。22.2%的患者PainDETECT问卷(PD-Q)评分≥19分提示很可能存在神经病理性疼痛,64.9%评分≤12分提示无显著神经病理性成分。神经病理性疼痛评分与DAPSA(r=0.46,p<0.0001)及ASDAS-CRP(r=0.42,p<0.01)呈中度正相关。

要点

  • 22.2%的SpA患者PD-Q评分≥19分,提示很可能存在神经病理性疼痛。
  • 女性阵发性疼痛和诱发性疼痛评分显著更高(p<0.05)。
  • 肥胖患者NPSI所有子评分均显著更高(p<0.05)。

核心结论

  • 神经病理性疼痛在SpA患者中普遍存在,且与疾病活动度评估和管理显著相关。
  • 作者认为应将神经病理性疼痛评估整合到SpA临床评估中,以有效制定个体化治疗方案并改善患者结局。

研究设计与样本

  • 横断面研究,在两家三级风湿病中心纳入177例确诊SpA的患者,涵盖中轴型SpA、银屑病关节炎和未分化外周型SpA。
  • 收集人口学与临床特征、合并症及当前治疗数据,采用PainDETECT问卷(PD-Q)和神经病理性疼痛症状量表(NPSI)评估神经病理性疼痛。
  • 统计分析包括描述性统计、t检验和Pearson相关性分析,评估神经病理性疼痛评分与临床疾病活动度指数之间的关系。

主要发现

  • 177例患者中,22.2%的PD-Q评分≥19分(很可能存在神经病理性疼痛),64.9%评分≤12分(提示无显著神经病理性成分),PD-Q平均评分为11.5±10.1。
  • 亚组分析显示女性阵发性疼痛和诱发性疼痛评分显著更高(p<0.05),肥胖患者NPSI所有子评分均显著更高(p<0.05)。
  • 神经病理性疼痛评分与临床疾病活动度指数呈中度正相关:DAPSA(r=0.46,p<0.0001)和ASDAS-CRP(r=0.42,p<0.01)。

关键数值与推荐

  • PD-Q评分≥19分定义为很可能存在神经病理性疼痛,≤12分提示无显著神经病理性成分。
  • 神经病理性疼痛评估采用PainDETECT问卷(PD-Q)和神经病理性疼痛症状量表(NPSI)。
  • 神经病理性疼痛评分与DAPSA的相关系数r=0.46(p<0.0001),与ASDAS-CRP的相关系数r=0.42(p<0.01)。

临床怎么用

  • 作者认为应将神经病理性疼痛评估整合到SpA的临床评估中,以有效制定个体化治疗方案并改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the prevalence and characteristics of neuropathic pain in patients with various subtypes of spondyloarthritis (SpA), including axial SpA (axSpA), psoriatic arthritis (PsA), and undifferentiated peripheral SpA (p-SpA). Additionally, the study sought to identify potential risk factors associated with the presence or severity of neuropathic pain and to investigate its impact on clinical disease activity assessment. METHODS: We conducted a cross-sectional study at two tertiary rheumatology centers, enrolling patients diagnosed with SpA. Data on demographic and clinical characteristics, comorbidities, and current therapies were collected. Neuropathic pain was assessed using the PainDETECT Questionnaire (PD-Q) and the Neuropathic Pain Symptom Inventory (NPSI). Statistical analyses included descriptive statistics, t-tests, and Pearson's correlations to evaluate the relationships between neuropathic pain scores and clinical disease activity indices. RESULTS: The study included 177 patients. Of these, 22.2% had a PD-Q score ≥19, showing a high likelihood of neuropathic pain, while 64.9% scored ≤12, suggesting the absence of significant neuropathic components. The mean PD-Q score was 11.5 ± 10.1. Subgroup analyses showed that females had significantly higher scores for paroxysmal and evoked pain (p < 0.05), and obese patients had significantly higher scores across all NPSI subscores (p < 0.05). Moderate positive correlations were found between neuropathic pain scores and clinical disease activity indices, such as DAPSA (r = 0.46, p < 0.0001) and ASDAS-CRP (r = 0.42, p < 0.01). CONCLUSIONS: Neuropathic pain is prevalent among patients with SpA and is significantly associated with disease activity assessments and management. This study highlights the importance of integrating neuropathic pain evaluation into the clinical assessment of SpA to tailor treatment approaches effectively and improve patient outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lopalco G, Vescovo SD, Morrone M, et al. Neuropathic pain in spondyloarthritis: Decoding its prevalence, risk factors, and impact on disease activity. Semin Arthritis Rheum. 2024. PMID: 39357168. doi:10.1016/j.semarthrit.2024.152557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。